MedTrace Logo

Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer

NCT05059951 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2024-06-04

No results posted yet for this study

Summary

Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Immune checkpoint inhibitor

Chemotherapy follow the guild line.

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    lead OTHER

Principal Investigators

  • Yongchang Zhang, MD · Hunan Cancer Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-03
Primary Completion
2026-09-15
Completion
2028-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059951 on ClinicalTrials.gov